BRIEF-GlaxoSmithKline says Dolutegravir granted FDA priority review
LONDON Feb 15 (Reuters) - GlaxoSmithKline Plc : * Dolutegravir granted FDA priority review * FDA has assigned Dolutegravir a prescription drug user fee act (PDUFA) target
date of 17 August 2013 * Viiv Healthcare announces FDA priority review designation for dolutegravir as
a potential treatment for hiv infection * Source text
DAVOS, Switzerland - Central banks have done their best to rescue the world economy by printing money and politicians must now act fast to enact structural reforms and pro-investment policies to boost growth, central bankers said on Saturday.